Camonsertib
Camonsertib[edit | edit source]
Camonsertib is an investigational small molecule inhibitor that targets the ATR kinase (Ataxia Telangiectasia and Rad3-related protein). It is being studied for its potential use in the treatment of various types of cancer, particularly those that exhibit defects in the DNA damage response pathways.
Mechanism of Action[edit | edit source]
Camonsertib functions by inhibiting the activity of ATR kinase, a critical enzyme involved in the cellular response to DNA damage. ATR plays a key role in the DNA damage checkpoint, a control mechanism that ensures the integrity of the genome by pausing the cell cycle to allow for DNA repair. By inhibiting ATR, Camonsertib disrupts this checkpoint, leading to the accumulation of DNA damage in cancer cells, ultimately resulting in cell death. This mechanism is particularly effective in cancer cells that are already compromised in their ability to repair DNA, such as those with mutations in the BRCA1 or BRCA2 genes.
Clinical Development[edit | edit source]
Camonsertib is currently undergoing clinical trials to evaluate its safety and efficacy in humans. These trials are exploring its use as a monotherapy as well as in combination with other anticancer agents. The focus is on cancers that are reliant on ATR for survival due to existing defects in other DNA repair pathways.
Potential Applications[edit | edit source]
The primary application of Camonsertib is in the treatment of cancers with specific genetic backgrounds that make them susceptible to ATR inhibition. This includes breast cancer, ovarian cancer, and prostate cancer with BRCA mutations. Additionally, Camonsertib may be beneficial in treating cancers that have developed resistance to other forms of therapy, such as chemotherapy or PARP inhibitors.
Side Effects and Safety[edit | edit source]
As with many targeted therapies, the side effects of Camonsertib are still being characterized through clinical trials. Commonly observed side effects in early studies include fatigue, nausea, and hematological effects such as anemia and thrombocytopenia. The safety profile of Camonsertib is an important aspect of ongoing research, as it will determine the feasibility of its use in broader patient populations.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
